Requisition Update

The NGS Solid Tumor Oncology Office Requisition has just been updated to streamline the ordering process for our clients. The requisition has been added to our website and is available for download here. Please contact our Client Services team to order printed copies.

• NEW - NGS Solid Tumor Oncology Office: version 072121

 

Test Updates

Hereditary Cancer Panel name changes & NY approval: Effective August 2, 2021, NeoLINK and online orders will display updated test names for hereditary cancer panels. Testing is performed by send-out to Fulgent Genetics, and patient consent is required. All seven tests are New York State-approved. Our writeable Hereditary Cancer Panel Requisition and website's test directory are current with the new names shown below.

• Bone Marrow Failure NGS Panel – outgoing name Bone Marrow Failure Syndrome Panel
• BRCA1 and BRCA2 Focus Panel – outgoing name BRCA1/2 Mutation & Del/Dup Analysis
• BRCA1 Single Gene (Germline) – outgoing name BRCA1 Mutation & Del/Dup Analysis
• BRCA2 Single Gene (Germline) – outgoing name BRCA2 Mutation & Del/Dup Analysis
• Colorectal Cancer Focus Panel (Germline) – outgoing name Lynch Syndrome
• Full Comprehensive Cancer Panel (Germline) – outgoing name Comprehensive Hereditary Cancer Panel
• Full Focus Cancer Panel (Germline) – new listing in NeoLINK and online orders

 

InVisionFirst^®-Lung Liquid Biopsy reflex after tissue QNS: Also effective August 2, 2021 clients placing online orders will have the option to order NeoTYPE^® Lung Tumor Profile or NeoTYPE^® Discovery Profile on lung tissue with reflex to InVisionFirst^®-Lung Liquid Biopsy if the tissue NGS testing is unsuccessful. This reflex option is already available on our NGS Solid Tumor and Lung Cancer Requisitions and will be available for interfaced orders in September. For interface ordering options meanwhile, please see the downloadable document in the Interface section below.

 

Test Discontinuation

Effective August 2, 2021, the following tests will be discontinued: FGFR CDx Mutation Analysis, MLL-PTD Mutation Analysis, and THxID BRAF Mutation Analysis by PCR for Melanoma. The decision to discontinue is based on volume and operational workflow requirements. Alternative suggestions, if available, are listed below.

• FGFR CDx Mutation Analysis (CPT 0154U)
  Alternative test suggestions: NeoTYPE^® Other Solid Tumor Profile and the Targeted Solid Tumor NGS Fusion Panel is recommended for detection of FGFR3 point mutations in addition to FGFR3 and FGFR2 rearrangements in urothelial carcinoma.
• MLL-PTD Mutation Analysis (CPT 81479x1)
  Alternative test suggestions: There is no alternative option offered at Neo. A comparable test is offered by Knight Diagnostic Laboratories at Oregon Health & Science University: MLL Partial Tandem Duplication (Acute Myeloid Leukemia). (Send-outs will not be available)
• THxID BRAF Mutation Analysis by PCR for Melanoma (CPT 81210)
  Alternative test suggestions: BRAF Mutation Analysis includes qualitative detection of V600 mutations E, K, D, and others, plus other significant exon 15 mutations. For an NGS option, the RAS/RAF Panel and the NeoTYPE^® Melanoma Profile are available.

 

The CPT Codes provided are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

**ATTENTION INTERFACE CLIENTS AND IT STAFF**

Interface related test changes will occur on August 2, 2021.

To view the interface test codes impacted, please click here for a downloadable document.

If you have interface questions, please contact InterfaceTeam@Neogenomics.com.

Additional Announcements

HER2 Breast FISH: JUL-DEC 2021 Assessment

Available Now: The Jul - Dec 2021 assessment for HER2 breast FISH that tech only clients can utilize is now available in NeoUniversity. NeoGenomics offers world-class educational programs as an additional benefit to all of our clients. Please visit NeoUniversity for more information.